Day Two At ODAC: Reviewing Drugs To Treat T-Cell Lymphoma In A Difficult Class
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA appears to have more concerns with Gloucester's HDAC inhibitor Istodax (romidepsin) than with Allos' Folotyn (pralatrexate).
You may also be interested in...
Gloucester's Istodax Gains FDA Approval Ahead Of New Regulatory Requirements
With FDA's approval a week ahead of the PDUFA date, Gloucester Pharmaceuticals will bring its first product to market, the second HDAC inhibitor approved in cancer.
Gloucester's Istodax Gains FDA Approval Ahead Of New Regulatory Requirements
With FDA's approval a week ahead of the PDUFA date, Gloucester Pharmaceuticals will bring its first product to market, the second HDAC inhibitor approved in cancer.
ODAC Sides With FDA: Evidence For Elderly AML Drugs Can't Stand On Single-Arm Trials
Feasible or not, randomized controlled trials are needed before approval of Genzyme's Clolar and Vion's Onrigin to treat elderly acute myeloid leukemia patients.